DEA Lifts Research Quotas 67% as GH Research Joins Late-Stage CNS Trials
The DEA raised its 2026 production quotas for controlled research compounds by 67%, underpinning accelerating clinical activity in CNS therapeutics. GH Research is named among five companies advancing late-stage candidates toward potential regulatory decisions.
1. CNS Sector Approaches Commercial Inflection
The DEA’s 67% increase in 2026 production quotas for controlled research compounds reflects expanding late-stage activity across central nervous system therapeutics, with multiple candidates nearing FDA review and growing pharmaceutical capital deployment.
2. GH Research Advances Pipeline Toward FDA Decisions
GH Research is one of five CNS-focused developers advancing candidates in late-stage trials for treatment-resistant depression and related disorders, positioning itself to leverage regulatory momentum and increased research capacity for potential near-term approvals.